fda glp‑1 compounding restriction
3 Reasons FDA Cuts Prescription Weight Loss Access?
The FDA is cutting access to prescription weight-loss drugs by removing three key GLP-1s from the 503B bulk list, a move that will raise costs, limit compounding and delay patient treatment. When an internal audit uncovered 15 non-compliant specimens, one pharmacy owner realized that the FDA’s recent orders are